1. Long-Term Complications, Immunologic Effects, and Role of Passage for Outcome in Mesenchymal Stromal Cell Therapy 
Lena von Bahr, Berit Sundberg, Lena Lönnies, Birgitta Sander, Holger Karbach, Hans Hägglund, Per Ljungman, Britt Gustafsson, Helen Karlsson, Katarina Le Blanc, Olle Ringdén 
Biology of Blood and Marrow Transplantation 
Volume 18, Issue 4, Pages (April 2012)
DOI: /j.bbmt
Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
In vitro reactivity to MSC measured before and after systemic MSC treatment, with each individual compared with himself/herself. Measured in MLC and with stimulation by PHA. No change in reactivity before and after treatment could be found.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Levels of IL-2 receptors in blood before and at weekly intervals after MSC treatment. Each individual compared with himself/herself. A significant decline in IL-2 receptors was found 1 week after MSC treatment.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
Comparison of in vitro inhibition of patient PBMCs by MSC treatment in clinical responders and nonresponders. Measured in MLC and with stimulation by PHA. No correlation was found between in vitro results and clinical response.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4
OS in GVHD patients treated with MSCs from both early passage (1-2) and late passage (3-4) (P < .01).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions